CG Oncology, Inc. (CGON) Return on equity 2024–2025
CG Oncology, Inc. (CGON) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-21.4%FY2025 · since FY2024: -12.0% → -21.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -21.4% | -9.4 pp |
| FY2024 | -12.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CGON financial trends
CGON RevenueCGON Net incomeCGON Net marginCGON Gross profitCGON Gross marginCGON Operating incomeCGON Operating marginCGON Operating cash flowCGON Free cash flowCGON Capital expendituresCGON Stock buybacksCGON Dividends paidCGON Total assetsCGON Total liabilitiesCGON Shareholders’ equityCGON overview →